Literature DB >> 8827425

Concentration and microheterogeneity glycophorms of alpha-1-acid glycoprotein in major depressive disorder.

A Sluzewska1, J K Rybakowski, M Sobieska, K Wiktorowicz.   

Abstract

Serum alpha-1-acid glycoprotein (AGP) concentration and its microheterogeneity were measured in 46 patients with major depressive disorder and in 20 age- and sex-matched controls. The changes in major microheterogeneity of AGP were expressed as reactivity coefficient (AGP-RC). Also measured were the levels of C-reactive protein as well as leukocyte, neutrophil and monocyte counts. The results obtained showed that two thirds of the depressed patients studied, exhibited some immune disturbances during acute episode: first with a high AGP and high AGP-RC, and secondly with a low AGP-RC. The patients with the highest AGP-RC and higher AGP values had a longer duration of the illness and of the last depressive episode, a higher resistance to previous treatments, and a higher monocyte count. The character of the changes in the microheterogeneity of AGP bears some similarity to those observed in other diseases with immunological disturbances.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827425     DOI: 10.1016/0165-0327(96)00026-2

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

1.  Reference distributions for the positive acute phase proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: a comparison of a large cohort to the world's literature.

Authors:  R F Ritchie; G E Palomaki; L M Neveux; O Navolotskaia
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response.

Authors:  M Maes; R Verkerk; E Vandoolaeghe; F Van Hunsel; H Neels; A Wauters; P Demedts; S Scharpé
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

3.  Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder.

Authors:  Cengiz Tuglu; S Hakan Kara; Okan Caliyurt; Erdal Vardar; Ercan Abay
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

4.  Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.

Authors:  M Maes; H Y Meltzer; P Buckley; E Bosmans
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 5.  Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis.

Authors:  Annamaria Cattaneo; Flavia Macchi; Giona Plazzotta; Begni Veronica; Luisella Bocchio-Chiavetto; Marco Andrea Riva; Carmine Maria Pariante
Journal:  Front Cell Neurosci       Date:  2015-03-31       Impact factor: 5.505

6.  Exploiting lectin affinity chromatography in clinical diagnosis.

Authors:  P R Satish; A Surolia
Journal:  J Biochem Biophys Methods       Date:  2001-10-30

7.  Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.

Authors:  Chenhua Zhang; Katherine N Schumacher; Eric D Dodds; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-07-09       Impact factor: 3.318

8.  Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression.

Authors:  Sokratis E Karaoulanis; Katerina A Rizouli; Andreas A Rizoulis; Nikiforos V Angelopoulos
Journal:  BMC Psychiatry       Date:  2014-06-04       Impact factor: 3.630

9.  Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms.

Authors:  Kevin A Davies; Ella Cooper; Valerie Voon; Jeremy Tibble; Mara Cercignani; Neil A Harrison
Journal:  Mol Psychiatry       Date:  2020-05-26       Impact factor: 15.992

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.